Anlon Healthcare Limited, a research-driven chemical manufacturing company, will be updated upon filing with the Roc on the Securities and Exchange Board of India (SEBI) for its Draft Red Herring Prospectus (DRHP) on October 9, 2024.
Specializing in high-purity pharmaceutical intermediates and active pharmaceutical ingredients (APIs), the company serves various sectors, including pharmaceuticals, nutraceuticals, personal care, and veterinary products.
The upcoming Anlon Healthcare Limited IPO aims to raise capital for expanding production capabilities and enhancing market presence.
Company Overview:
Anlon Healthcare Limited is a research and development (R&D) driven chemical manufacturing company.
Product Range:
Specializes in the manufacturing of high-purity advanced pharmaceutical intermediates (raw materials for active pharmaceutical ingredients) and active pharmaceutical ingredients (APIs).
Applications:
- APIs are used in various finished dosage forms like tablets, capsules, ointments, syrups, etc.
- Ingredients for nutraceuticals, personal care products, and animal health products.
Pharmaceutical Standards:
Products are manufactured in accordance with major pharmacopeia standards, including Indian (IP), British (BP), European (EP), Japanese (JP), and U.S. (USP) standards.
Diverse Product Categories
- Pharmaceutical intermediates
- Nutraceutical APIs
- Ingredients for personal care and veterinary APIs
Compliance:
The company adheres to both Indian and international pharmacopeia standards ensuring global market reach.
Anlon Healthcare Limited IPO Listing Dates
| IPO Particulars | Details |
| IPO Date | Soon |
| Face Value | ₹10 Per Share |
| Price Band | Not Applicable |
| Lot Size | Not Decided yet |
| Total Issue Size | Up to ₹[●] Lakh |
| Fresh Issue | Fresh Issue of up to 1,40,00,000 Equity Shares |
| Offer for Sale | Not Applicable |
| Issue Type | Book Built Issue IPO |
| Listing At | BSE, NSE |
| Pre-Issue and Post-Issue Shareholding | 3,98,51,500 Equity Shares of face value of ₹10 each |
Read More – ONGC Green Energy IPO: Is It A Golden Opportunity for Investors?
Anlon Healthcare Limited Financial Statements –
| Particulars | For the Three-Month Period Ended | March 31, 2024 | March 31, 2023 | March 31, 2022 |
| Equity Share Capital | ₹1,600.00 | ₹1,600.00 | ₹1,200.00 | ₹1,200.00 |
| Net Worth | ₹2,556.83 | ₹2,103.14 | ₹737.43 | ₹155.43 |
| Total Revenue (including Other Income) | ₹3,789.34 | ₹6,669.19 | ₹11,312.00 | ₹5,753.64 |
| Profit/(Loss) After Tax | ₹453.69 | ₹965.71 | ₹582.00 | ₹10.77 |
| Earnings per Equity Share | ₹2.84 | ₹6.68 | ₹4.85 | ₹0.09 |
| Net Asset Value per Share (in ₹) | ₹15.98 | ₹14.55 | ₹6.15 | ₹1.30 |
| Total Borrowings (including Current Maturities) | ₹7,292.71 | ₹7,456.31 | ₹6,638.67 | ₹6,032.30 |
Conclusion
The IPO of Anlon Healthcare Limited represents a significant growth opportunity, showcasing a solid financial performance with increasing revenue and profit margins. The funds raised will support operational expansion and a commitment to quality in the healthcare sector. Investors can look forward to a promising venture as Anlon Healthcare positions itself for future success in the evolving healthcare landscape.
This Website is not promote any investment and not advice to invest. This Website is not liable for your profit or loss with this information. This blog is just provide information for educational purpose.